InsiderSignal.AI

InsiderSignal.ai

CRSP - Crispr Therapeutics AG

Insider Sale by Kasinger James R. (GC, Secretary)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Kasinger James R., serving as GC, Secretary at Crispr Therapeutics AG (CRSP), sold 3,450 shares at $48.26 per share, for a total transaction value of $166,497.00. Following this transaction, Kasinger James R. now holds 91,240 shares of CRSP.

This sale represents a 4.00% decrease in Kasinger James R.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 17, 2026, 1 day after the trade was made.

Crispr Therapeutics AG operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Kasinger James R.

GC, Secretary

James R. Kasinger is General Counsel and Secretary of CRISPR Therapeutics AG (CRSP), a role he has held since May 2017, where he leads legal, governance, corporate compliance, and intellectual property matters.[[1]](https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-appoints-james-r-kasinger-as-general-counsel-1)[[3]](https://crisprtx.com/about-us/leadership/jim-kasinger) A highly accomplished lawyer with nearly 20 years of experience at the time of his appointment, Kasinger previously served as General Counsel and Secretary at Moderna Therapeutics (April 2014–May 2017) and General Counsel at PlumChoice, Inc., and was a partner at Goodwin Procter LLP, representing life sciences and technology companies through financings, IPOs, mergers, and sales; he began his career at Testa, Hurwitz & Thibeault.[[1]](https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-appoints-james-r-kasinger-as-general-counsel-1)[[3]](https://crisprtx.com/about-us/leadership/jim-kasinger) Kasinger holds a J.D. *cum laude* from Boston College Law School and a B.A. *magna cum laude* from Wheaton College.[[1]](https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-appoints-james-r-kasinger-as-general-counsel-1) As a corporate insider, he owns approximately 74,880–87,227 shares of CRSP stock (valued at over $3 million as of early 2025) and has engaged in recent transactions, including RSU conversions and sales for tax withholding in February 2026, such as selling 2,112 shares at $52.58 and 11,542 shares totaling $619,459 on February 19, 2025.[[2]](https://www.gurufocus.com/insider/40547/james-r.-kasinger)[[4]](https://www.stocktitan.net/sec-filings/CRSP/form-4-crispr-therapeutics-ag-insider-trading-activity-d6a8823b1883.html)[[5]](https://www.marketbeat.com/instant-alerts/crispr-therapeutics-nasdaqcrsp-general-counsel-sells-11104896-in-stock-2026-02-20/)

View full insider profile →

Trade Price

$48.26

Quantity

3,450

Total Value

$166,497.00

Shares Owned

91,240

Trade Date

Monday, March 16, 2026

1 days ago

SEC Filing Date

Tuesday, March 17, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Crispr Therapeutics AG

Company Overview

No company information available
View news mentioning CRSP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4869055

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime